

## Marleen H.J. van den Horst



As partner and head of the IP & Technology Practice Group of the Netherlands based law firm BarentsKrans NV, Marleen van den Horst has extensive experience in litigating IP cases before various courts, both interim injunction and final relief proceedings. With a focus on patents and technology, she is frequently involved in multi-jurisdictional litigation for –mainly- foreign clients. Client-driven, Marleen has specialised in patent litigation and regulatory proceedings in the pharmaceutical, life sciences and healthcare industry. Marleen and her team have conducted patent/SPC litigation and regulatory proceedings involving molecules such as ciclosporin, omeprazol, alendronate, fluvastatin, escitalopram, esomeprazol and modafinil. Marleen assists clients in drafting and negotiating licences, technology transfer and distribution agreements. Marleen co-heads BarentsKrans' Healthcare & Life Sciences industry group, which combines specialist in house knowhow in the pharmaceutical and life sciences arena. Marleen is a regular speaker at international conferences, such as Fordham's IP conference, C5 conferences on Pharma & Biotech Patent litigation, LES, Biobusiness Masterclass. She is a member of the IP Committee of the Dutch Bar Association, of the IP Committee of the Dutch biotech organisation NIABA and member of the Advisory Board of various non for profit organisations.

### Important cases include:

- Generics v. Smith Kline Laboratories: patent infringement and regulatory problems regarding market authorisations. District Court, Court of Appeal, Supreme Court and ECJ (Luxembourg);
- KGS & Eurosensory v. Tieman & BEE: patent infringement and invalidity in respect of electronic braille equipment. Preliminary injunction proceedings and final relief proceedings before District Court and Court of Appeal;
- Petterson & Salin v. NemoQ, Objecta, and Municipality of Eindhoven: various patent infringement and invalidity proceedings in respect of electronic queue system. Preliminary injunction proceedings and final relief proceedings before the District Court and Court of Appeal;
- Blommaert v. Baeck: patent infringement and invalidity proceedings in respect of hatches for ships. Preliminary injunction proceedings and final relief proceedings before the District Court and Court of Appeal;
- Merck Generics and Hexal Pharma v. AstraZeneca: patent infringement and invalidity proceedings re: omeprazole. Preliminary injunction and final relief proceedings before the District Court and Court of Appeal;
- Tiefenbacher et al v. Lundbeck: patent infringement/invalidity proceedings and regulatory proceedings re: escitalopram. Final relief proceedings in first instance and appeal;
- Stada v. AstraZeneca: invalidity proceedings re: esomeprazol.

**Contact Details:** T:+ 31 70 3760621, E: [vdhorst@barentskrans.nl](mailto:vdhorst@barentskrans.nl), website: [www.barentskrans.nl](http://www.barentskrans.nl)